MARKET

INDP

INDP

Indaptus Therapeutics Inc
NASDAQ
1.600
-0.100
-5.88%
After Hours: 1.590 -0.01 -0.63% 19:35 04/02 EDT
OPEN
1.650
PREV CLOSE
1.700
HIGH
1.655
LOW
1.570
VOLUME
42.70K
TURNOVER
--
52 WEEK HIGH
19.91
52 WEEK LOW
1.520
MARKET CAP
3.59M
P/E (TTM)
-0.0741
1D
5D
1M
3M
1Y
5Y
1D
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight
TipRanks · 20h ago
INDAPTUS THERAPEUTICS INC - APPOINTS YU DING AS CFO EFFECTIVE APRIL 1, 2026 - SEC FILING
Reuters · 20h ago
Indaptus Therapeutics names Yu Ding CFO after Nir Sassi resignation
Reuters · 20h ago
Indaptus Therapeutics files Form 3 initial beneficial ownership statement for Yun Yao
Reuters · 1d ago
Indaptus Therapeutics files Form 3; Sino Lion Ventures reports beneficial ownership
Reuters · 1d ago
Indaptus Therapeutics files Form 3 for CEO Junyi Dai initial beneficial ownership statement
Reuters · 1d ago
Weekly Report: what happened at INDP last week (0323-0327)?
Weekly Report · 5d ago
Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million
Reuters · 03/26 18:10
More
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Webull offers Indaptus Therapeutics Inc stock information, including NASDAQ: INDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INDP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INDP stock methods without spending real money on the virtual paper trading platform.